ES2393826T3 - Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos transgénicos de idiotipo humano - Google Patents

Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos transgénicos de idiotipo humano Download PDF

Info

Publication number
ES2393826T3
ES2393826T3 ES11161775T ES11161775T ES2393826T3 ES 2393826 T3 ES2393826 T3 ES 2393826T3 ES 11161775 T ES11161775 T ES 11161775T ES 11161775 T ES11161775 T ES 11161775T ES 2393826 T3 ES2393826 T3 ES 2393826T3
Authority
ES
Spain
Prior art keywords
rat
locus
human
artificial
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11161775T
Other languages
English (en)
Spanish (es)
Inventor
Ronald Buelow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OMT Inc
Original Assignee
OMT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40111008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2393826(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by OMT Inc filed Critical OMT Inc
Application granted granted Critical
Publication of ES2393826T3 publication Critical patent/ES2393826T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
ES11161775T 2007-06-01 2008-05-30 Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos transgénicos de idiotipo humano Active ES2393826T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94161907P 2007-06-01 2007-06-01
US914619P 2007-06-01
US4432408P 2008-04-11 2008-04-11
US44324P 2008-04-11

Publications (1)

Publication Number Publication Date
ES2393826T3 true ES2393826T3 (es) 2012-12-28

Family

ID=40111008

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08769934T Active ES2372718T3 (es) 2007-06-01 2008-05-30 Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos de idiotipos humanos transgénicos.
ES12187787.2T Active ES2664218T3 (es) 2007-06-01 2008-05-30 Composiciones y procedimientos de inhibición de genes de inmunoglobulinas endógenas y de producción de anticuerpos idiotípicos humanos transgénicos
ES11161775T Active ES2393826T3 (es) 2007-06-01 2008-05-30 Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos transgénicos de idiotipo humano

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES08769934T Active ES2372718T3 (es) 2007-06-01 2008-05-30 Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos de idiotipos humanos transgénicos.
ES12187787.2T Active ES2664218T3 (es) 2007-06-01 2008-05-30 Composiciones y procedimientos de inhibición de genes de inmunoglobulinas endógenas y de producción de anticuerpos idiotípicos humanos transgénicos

Country Status (21)

Country Link
US (6) US8703485B2 (OSRAM)
EP (4) EP3382022A1 (OSRAM)
JP (6) JP5823690B2 (OSRAM)
KR (4) KR101886610B1 (OSRAM)
CN (1) CN101784664B (OSRAM)
AT (1) ATE522611T1 (OSRAM)
AU (1) AU2008259939B2 (OSRAM)
CA (2) CA2688834C (OSRAM)
CY (1) CY1120383T1 (OSRAM)
DK (3) DK2602323T3 (OSRAM)
ES (3) ES2372718T3 (OSRAM)
HR (1) HRP20180506T1 (OSRAM)
HU (1) HUE037302T2 (OSRAM)
IL (2) IL202302A (OSRAM)
LT (1) LT2602323T (OSRAM)
NZ (1) NZ581396A (OSRAM)
PL (3) PL2336329T3 (OSRAM)
PT (3) PT2336329E (OSRAM)
SG (2) SG10201509853UA (OSRAM)
SI (1) SI2602323T1 (OSRAM)
WO (1) WO2008151081A1 (OSRAM)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523661T3 (es) 2004-07-22 2014-11-28 Erasmus University Medical Center Rotterdam Moléculas de unión
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
CN102177235A (zh) * 2008-09-08 2011-09-07 赛莱克蒂斯公司 切割来自谷氨酰胺合成酶基因的dna靶序列的大范围核酸酶变体及其用途
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
US20110314563A1 (en) 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
NO2792236T3 (OSRAM) 2009-07-08 2018-04-14
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
CN105695415A (zh) * 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
SG194089A1 (en) * 2011-04-27 2013-11-29 Amyris Inc Methods for genomic modification
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
IL293650B2 (en) 2011-09-21 2024-10-01 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20250021626A (ko) 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR101904508B1 (ko) * 2012-04-25 2018-10-04 리제너론 파마슈티칼스 인코포레이티드 큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
MX364449B (es) 2012-06-12 2019-04-26 Regeneron Pharma Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
MX2014015204A (es) * 2012-06-12 2015-08-07 Genentech Inc Metodos y composiciones para generar alelos con inactivacion condicional.
EP3653049B1 (en) * 2012-12-14 2023-09-13 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2829376T3 (es) 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
EP2986709A4 (en) * 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
KR20200136508A (ko) 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
EP3521437B1 (en) 2014-11-21 2025-01-15 Regeneron Pharmaceuticals, Inc. Methods for targeted genetic modification using paired guide rnas
SG11201704646YA (en) 2014-12-19 2017-07-28 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
US11008391B2 (en) 2015-08-11 2021-05-18 WuXi Biologics Ireland Limited Anti-PD-1 antibodies
US20180230238A1 (en) * 2015-08-24 2018-08-16 Trianni, Inc Enhanced production of immunoglobulins
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
CA3034706A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
PT3558369T (pt) 2016-12-21 2025-05-06 Cephalon Llc Anticorpos que se ligam especificamente à il-15 humana e suas utilizações
KR102777514B1 (ko) 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US11021540B2 (en) 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
AU2018331421A1 (en) 2017-09-13 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
BR112020013086A2 (pt) 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US12428471B2 (en) * 2018-06-13 2025-09-30 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
US12102070B2 (en) * 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
EP3830124A1 (en) 2018-08-01 2021-06-09 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CA3127520A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
AU2020252556A1 (en) 2019-04-05 2021-10-21 Teneobio, Inc. Heavy chain antibodies binding to PSMA
US20220251232A1 (en) 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021058795A2 (en) 2019-09-27 2021-04-01 Stark Labs Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
WO2022106663A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022106665A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
US12371475B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
JP2025508086A (ja) 2022-03-09 2025-03-21 オルデラン バイオテクノロジー 抗ｃｄ１６０膜貫通型アイソフォーム抗体
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE4119749A1 (de) 1991-06-15 1992-12-17 Claas Ohg Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5795974A (en) 1993-12-10 1998-08-18 University Of Utah Research Foundation Mycoplasma arthritidis superantigen
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6372956B1 (en) * 1998-12-31 2002-04-16 The J. David Gladstone Institutes Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
WO2001084921A2 (en) * 2000-04-24 2001-11-15 Wyeth Transgenic animal
US7129084B2 (en) * 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20040199934A1 (en) 2001-08-20 2004-10-07 Hess John W Transgenic rodents as animal moldels for modulation of b1 bradykinin receptor protein
DE60236182D1 (de) * 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
EP2368982A3 (en) * 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US20060153826A1 (en) * 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20040158880A1 (en) * 2003-02-05 2004-08-12 Roland Buelow Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CN1835974A (zh) * 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005019463A1 (en) * 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) * 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
KR101386690B1 (ko) 2004-03-04 2014-04-22 도쿠리츠교세이호진 고쿠리츠간켄큐센터 래트 배아 줄기 세포
ES2523661T3 (es) 2004-07-22 2014-11-28 Erasmus University Medical Center Rotterdam Moléculas de unión
WO2006047367A2 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
US20060130157A1 (en) * 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
CA2599875A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2325307A1 (en) 2005-03-15 2011-05-25 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
RU2435784C2 (ru) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PT2336329E (pt) * 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
EP2840892B1 (en) * 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences

Also Published As

Publication number Publication date
JP2022118217A (ja) 2022-08-12
EP2336329B8 (en) 2012-11-21
DK2336329T3 (da) 2013-01-07
PT2602323T (pt) 2018-04-02
US8907157B2 (en) 2014-12-09
KR101886610B1 (ko) 2018-08-09
PL2336329T3 (pl) 2013-04-30
NZ581396A (en) 2012-07-27
CN101784664A (zh) 2010-07-21
SI2602323T1 (en) 2018-05-31
CA2688834A1 (en) 2008-12-11
HUE037302T2 (hu) 2018-08-28
US10072069B2 (en) 2018-09-11
ES2372718T3 (es) 2012-01-25
US20190169270A1 (en) 2019-06-06
EP2602323A1 (en) 2013-06-12
JP6220827B2 (ja) 2017-10-25
JP2015204840A (ja) 2015-11-19
SG182144A1 (en) 2012-07-30
KR20170016518A (ko) 2017-02-13
ATE522611T1 (de) 2011-09-15
PL2602323T3 (pl) 2018-06-29
US20210253673A1 (en) 2021-08-19
AU2008259939B2 (en) 2014-03-13
JP2010529042A (ja) 2010-08-26
CY1120383T1 (el) 2019-07-10
EP2336329A1 (en) 2011-06-22
CA2688834C (en) 2020-01-07
EP2152880A4 (en) 2010-06-16
IL202302A (en) 2013-07-31
US8703485B2 (en) 2014-04-22
JP2020125360A (ja) 2020-08-20
CA3054224A1 (en) 2008-12-11
JP2014027947A (ja) 2014-02-13
JP2018000201A (ja) 2018-01-11
KR20150101475A (ko) 2015-09-03
IL202302A0 (en) 2011-08-01
EP2336329B1 (en) 2012-10-10
WO2008151081A8 (en) 2010-02-04
DK2152880T3 (da) 2011-11-28
JP5823690B2 (ja) 2015-11-25
IL220209A (en) 2013-11-28
EP2152880A1 (en) 2010-02-17
SG10201509853UA (en) 2015-12-30
EP3382022A1 (en) 2018-10-03
CN101784664B (zh) 2013-04-10
ES2664218T3 (es) 2018-04-18
HRP20180506T1 (hr) 2018-05-04
PT2336329E (pt) 2012-12-24
LT2602323T (lt) 2018-04-10
AU2008259939A1 (en) 2008-12-11
EP2602323B1 (en) 2018-02-28
HK1135138A1 (en) 2010-05-28
WO2008151081A1 (en) 2008-12-11
IL220209A0 (en) 2012-07-31
PT2152880E (pt) 2011-12-15
JP6712254B2 (ja) 2020-06-17
US9388233B2 (en) 2016-07-12
KR101703299B1 (ko) 2017-02-06
US20120090041A1 (en) 2012-04-12
CN102850452A (zh) 2013-01-02
EP2152880B1 (en) 2011-08-31
KR20180090395A (ko) 2018-08-10
KR20100037027A (ko) 2010-04-08
US20100212035A1 (en) 2010-08-19
KR101661357B1 (ko) 2016-09-29
DK2602323T3 (en) 2018-04-16
US20160311888A1 (en) 2016-10-27
KR102096731B1 (ko) 2020-04-02
US20090098134A1 (en) 2009-04-16
PL2152880T3 (pl) 2012-03-30

Similar Documents

Publication Publication Date Title
ES2393826T3 (es) Composiciones y métodos para inhibir genes endógenos de inmunoglobulinas y producir anticuerpos transgénicos de idiotipo humano
JP2010529042A6 (ja) 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法
HK1261736A1 (en) Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
HK1186493B (en) Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
HK1186493A (en) Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
HK1135138B (en) Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies